|


| |
 |
Fast Fact and Concept #05
Treatment of Nausea and Vomiting
Author(s): Hallenbeck, J.; Weissman, D. |
This Fast Fact & Concept reviews the commonly prescribed anti-emetics and
their mechanism of action. This can be used by attending physicians during
rounds or as a handout for a teaching conference. 
Educational Objective(s)
Understand the mechanism of action of different anti-emetics. Understand
how to select an anti-emetic based on the cause of nausea/vomiting.

What's the difference between Compazine (prochlorperazine) and
Phenergan (promethazine)? By understanding the pathophysiology of nausea
and targeting antiemetics to specific receptors, therapy can be optimized
and side effects minimized. An easy way to remember the causes of vomiting
is to use the VOMIT acronym. In the table below receptors
involved in different types of nausea are highlighted using this acronym.
Blockade of these receptors allows rational, focused therapy.
| Type of
Nausea |
Receptors
Causing Nausea |
Drug
Class Useful |
Examples
of DOC |
| Vestibular |
Cholinergic, Histaminic |
Anticholinergic, Antihistaminic |
Scopolamine patch, Promethazine |
| Obstruction
of Bowel caused by constipation* |
Cholinergic, Histaminic, ? 5HT3 |
Stimulate myenteric plexus |
Senna products |
| DysMotility
of upper gut ** |
Cholinergic, Histaminic, ? 5HT3 |
Prokinetics stimulate 5HT4
receptors |
Metoclopramide Cisapride |
| Infection,
Inflammation |
Cholinergic, Histaminic, ? 5HT3 |
Anticholinergic, Antihistaminic |
Promethazine |
| Toxins
stimulating the CTZ in the brain such as Opioids*** |
Dopamine 2, 5HT3 |
Antidopaminergic, 5HT3 Antagonist |
Prochlorperazine, Haloperidol,
Ondansetron |
* The most common cause of bowel obstruction is constipation. This is
especially problematic in patients on opioids. Treatment of nausea related
to mechanical bowel obstruction is controversial and stimulants, such as
senna may be inappropriate, especially if cramping is present.
** Dysmotility of the upper gut is a common, under-appreciated cause of
nausea, especially in patients on opioids or anticholinergic drugs, both
of which slow gut motility. Patients typically complain of early satiety
in contrast to other patients, who have fasting nausea. Metoclopramide is
contraindicated in Parkinson's Disease and renal failure. Cisapride has
numerous drug-drug interactions, so beware! Both prokinetics work poorly
if anticholinergic drugs are co-administered. So don't give promethazine
for this form of nausea!
*** Rising serum levels of opioids stimulate the chemotactic trigger zone
(CTZ), causing nausea. Minimizing fluctuating opioid levels, by using
long-acting agents where possible, can limit this form of nausea.
Prochlorperazine is the first-line suppository, haloperidol may be used
orally or parenterally. Ondansetron, a 5HT3 antagonist is a second-line
agent that can be used where antidopaminergic drugs are contraindicated,
such as in Parkinson's Disease.
Additional pearl: There is no good evidence supporting
the use of lorazepam as a sole agent for nausea. Sedated patients may be
more prone to aspiration. Listed below is a comparison of some commonly
used antiemetics:
Scopolamine: a very potent, pure anticholinergic agent.
Promethazine (Phenergan): antihistamine with potent anticholinergic
properties, very weak antidopaminergic agent. (So bad for opioid related
nausea.)
Prochlorperazine (Compazine): Potent antidopaminergic, weak
antihistamine, antichlonergic agent.
Haloperidol: Very potent anti-dopaminergic agent.
As you can see, Phenergan and Compazine are very different drugs.
Phenergan is useful for vertigo and gastroenteritis due to infections and
inflammation. Compazine is preferred for opioid related nausea.
References: Mannix KA. Palliation of nausea and vomiting.
Oxford Text Palliative Med. Second ed. 1998. Oxford. U. Press, NY.489-499.
Storey P, Knight CF. UNIPAC Four: Management of Selected Nonpain Symptoms
in the Terminally Ill. 1996. American Academy of Hospice and Palliative
Medicine. Can order via aahpm.org.
Fast Facts and Concepts are developed and distributed as part of the
National Internal Medicine Residency End-of-Life Education project, funded
by the Robert Wood Johnson Foundation.
DISCLAIMER CONCERNING MEDICAL INFORMATION - Health care providers should
exercise their own independent clinical judgment. Accordingly, the
official prescribing information should be consulted before any product is
used.
CONTACT
Dr. Weissman

|
|